Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

07/06/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

 

ASH 2018: ECHELON-2 trial

11/12/2018

Prof. Lorenz Trümper about the ECHELON-2 trial.

  • 00:05:21
 

Quarterly Focus on Hematology | CLL

10/01/2019

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

 

ASH 2018: Highlights

11/12/2018

Prof. Anas Younes summarizes some of his highlights of ASH 2018.

  • 00:05:24

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Meet the author 10/01/2019

Quarterly Focus on Hematology | CLL

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

Congresnieuws 11/12/2018

ASH 2018: AUGMENT trial

Prof. John Leonard highlights data from the AUGMENT trial as presented on ASH 2018. AUGMENT is a phase 3, multicenter, randomized trial of lenalidomide plus rituximab (R2) versus placebo plus rituximab was conducted in patients with R/R indolent non-Hodgkin lymphoma.

Congresnieuws 11/12/2018

ASH 2018: ACT 1-2

Presenter Francesco d'Amore summarizes the final results of the ACT-1/2 trial.

Congresnieuws 11/12/2018

ASH 2018: Highlights lymphoma

Dr. Martin Hutchings from Denmark talks about the first in-human trial he presented at ASH 2018 and mentions another congress highlight: the ECHELON-2 trial.

Meet the author 11/10/2018

Quarterly Hematology: highlights in Hodgkin Lymphoma

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Two high-impact international publications on Hodgkin Lymphoma of the past year will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consists of: Josée Zijlstra, MD, PhD, hematologist, VUmc Amsterdam Wouter Plattel, MD, PhD, hematologist, UMC Groningen Live video guests: HD18: Prof. Peter Borchmann, MD, PhD, hematologist, University Hospital of Cologne, Germany H10: Prof. Massimo Federico, MD, hematologist, University of Modena and Reggio Emilia, Italy

Meet the author 07/06/2018

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

Meet the author 22/03/2018

Quarterly Focus on Hemato-Oncology | Highlights in AML

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu has developed a new program format, the 'Quarterly Focus, which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. The selection for the first edition of Quarterly Focus on Hemato-Oncology has been made by prof. dr. Gert Ossenkoppele, VUmc Amsterdam, Netherlands. Three pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Prof. Gert Ossenkoppele, MD, hematologist, VUmc, Amsterdam, Netherlands; Prof. Gerwin Huls, MD, hematologist, UMCG, Groningen; Netherlands; Peter Valk, Ph.D., molecular biologist, Erasmus MC, Rotterdam, Netherlands. Selected publications Quarterly Hemato-Oncology: Midostaurin plus chemotherapy for acute myeloid leukemia with FLT mutation N Engl J Med 2017 Prof. Richard Schlenk, MD, hematologist TP53 and decitabine in AML and myelodysplastic syndromes N Engl J Med 2016 Dr. John S. Welch, MD, Ph.D., hematologist Precision Oncology in acute myeloid leukemia using a knowledge bank approach. Nature Genetics, January 2017 Elli Papaemmanuil, Ph.D., molecular geneticist Accreditation: This program will be submitted for accreditation at the EBAH and Dutch NIV.

Congresnieuws 25/06/2017

Clinical updates from the EHA 2017 part 1

The 22nd European Hematology Association (EHA) took place in Madrid, Spain, on 22-25 June 2017. An international multidisciplinary panel discussed a selection of topics and new data on hematology during a live program. They gave an answer to what this newly acquired knowledge means for clinical practice. Topics New immunotherapy data for lymphoma The mechanisms behind iron overload New diagnostic markers for ITP Speakers Alicia Rovó, MD – hematologist, University Hospital of Bern, Bern, Switzerland Sigrid Machherndl-Spandl, MD – hematologist, Elisabethinen Hospital, Linz, Austria Moderator Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands